key: cord-0272308-2qt85hfx
authors: Fristed, E.; Skirrow, C.; Meszaros, M.; Lenain, R.; Meepegama, U.; Cappa, S.; Aarsland, D.; Weston, J.
title: Evaluation of a speech-based AI system for early detection of Alzheimer's disease remotely via smartphones
date: 2021-10-20
journal: nan
DOI: 10.1101/2021.10.19.21264878
sha: eba078a7a33c57ae5cb7d14bea44e3378b43cb27
doc_id: 272308
cord_uid: 2qt85hfx

Background: Changes in speech, language, and episodic and semantic memory are documented in Alzheimer's disease (AD) years before routine diagnosis. Aims: Develop an Artificial Intelligence (AI) system detecting amyloid-confirmed prodromal and preclinical AD from speech collected remotely via participants' smartphones. Method: A convenience sample of 133 participants with established amyloid beta and clinical diagnostic status (66 A{beta} +, 67 A{beta} -; 71 cognitively unimpaired (CU), 62 with mild cognitive impairment (MCI) or mild AD) completed clinical assessments for the AMYPRED study (NCT04828122). Participants completed optional remote assessments daily for 7-8 days, including the Automatic Story Recall Task (ASRT), a story recall paradigm with short and long variants, and immediate and delayed recall phases. Vector-based representations from each story source and transcribed retelling were produced using ParaBLEU, a paraphrase evaluation model. Representations were fed into logistic regression models trained with tournament leave-pair-out cross-validation analysis, predicting A{beta} status and MCI/mild AD within the full sample and A{beta} status in clinical diagnostic subsamples. Findings: At least one full remote ASRT assessment was completed by 115 participants (mean age=69.6 (range 54-80); 63 female/52 male; 66 CU and 49 MCI/mild AD, 56 A{beta} + and 59 A{beta} -). Using an average of 2.7 minutes of automatically transcribed speech from immediate recall of short stories, the AI system predicted MCI/mild AD in the full sample (AUC=0.85 +/- 0.08), and amyloid in MCI/mild AD (AUC=0.73 +/- 0.14) and CU subsamples (AUC=0.71 +/- 0.13). Amyloid classification within the full sample was no better than chance (AUC=0.57 +/- 0.11). Broadly similar results were reported for manually transcribed data, long ASRTs and delayed recall. Interpretation: Combined with advanced AI language models, brief, remote speech-based testing offers simple, accessible and cost-effective screening for early stage AD. Funding: Novoic.

Pathological changes in Alzheimer's disease (AD) begin years before symptoms of dementia or the early clinical stages of mild cognitive impairment (MCI), and up to decades before More importantly, cognitively unimpaired individuals with biomarker evidence of both amyloid beta and tau pathology will not always develop clinical manifestations in their lifetime, and should only be considered at-risk for progression to AD, reserving diagnosis of AD to people with evidence of an AD cognitive phenotype 3 . Cognitive testing is thus crucial for an early diagnosis. Cognitive tests have been supported for use as endpoints of treatment efficacy early in the Alzheimer's continuum by regulatory bodies 4, 5 . However, traditional cognitive tests typically require significant qualified staff time to administer and score. In the case of amyloid All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 20, 2021. ; https://doi.org/10.1101/2021. 10.19.21264878 doi: medRxiv preprint positive asymptomatic subjects, only subtle impairments or longitudinal change are observable 6, 7 .

Cognitive test results often reflect simple indices of response accuracy or recall, ignoring differences in the content, structure and delivery of patients' responses to tasks. For episodic memory tests, such as tests of story recall, test performance does not typically differ between clinically unimpaired A + and A -individuals, but differences can be seen in the recall of proper nouns 8 , and the serial position of elements recalled 9 . Later in the disease course, differences are seen in rates of verbatim or paraphrased recall 10 , language density and pauses 11 .

There is a need for cognitive screening tools allowing fast and frequent assessment of the atrisk population. Speech data collected on ubiquitous digital devices represents an excellent candidate for this goal. Verbal memory tasks can be scored automatically using natural language processing technologies 12 , and augmented with acoustic and linguistic measures to further improve detection 11 . Recent methods in artificial intelligence (AI) enable extraction of more information-dense patterns from text data 13, 14 . We hypothesise that these could form the basis of speech biomarkers sensitive to earlier disease stages, possibly before overt cognitive decline (asymptomatic at-risk individuals).

Using speech elicited from a remotely self-administered story recall task, we aim to develop an AI-based system to (1) differentiate A + and A -subjects; (2) differentiate those with and without mild cognitive impairment. The test would be usable remotely for initial clinical screening to detect MCI and subtle signs of cognitive decline in amyloid-confirmed asymptomatic subjects (preclinical AD). Furthermore, we examine the performance of the index test compared to current standard-of-care in primary care referrals for MCI using a simulation approach.

The AMYPRED study (NCT04828122) is a prospective study with data collection planned before the index test was performed. The study uses a 2x2 cross-sectional design, combining amyloid status (A + and A -) and clinical status (cognitively unimpaired (CU) and MCI/mild AD). Reference standards for A positivity and clinical status were established prior to recruitment into the study. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 17 ; ability to use and access to a smartphone (Android 7 or above or iOS 11 or above); and access to the internet on a personal computer, notebook or tablet (supported operating systems and internet browser software documented in supplementary materials).

Exclusions comprised: current diagnosis of general anxiety disorder or major depressive disorder; recent (6-month) history of unstable psychiatric illness; history of stroke within the past 2 years or transient ischaemic attack or unexplained loss of consciousness in the last 12 months. Participants taking medications for AD symptoms were required to be on a stable dose for at least 8 weeks.

Participants underwent a clinical assessment via video call, followed by optional remote assessments daily using their personal digital devices for 7-8 days.

Cognitive tests part of the Preclinical Alzheimer's Cognitive Composite with semantic processing (PACC5) were administered and mean z-score was calculated as previously described 6 . The CDR 17 , assessing the severity of cognitive symptoms of dementia, was completed by experienced research staff and scored to deliver the CDR Global Score (CDR-G). Task modifications enabling remote assessment during the SARS-CoV-2 pandemic are detailed in supplementary materials. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

During telemedicine assessments, participants were supported to install the Novoic mobile application on their own smartphone. They were encouraged to complete optional unsupervised self-assessments daily for the following 7-8 days. Remote self-assessments included Automatic Story Recall Tests (ASRT), consisting of 18 short and 18 long story variants (mean of 119 and 224 words per story, and stimulus duration approx 1 minute and 1min 40 seconds, respectively). ASRTs were administered in triplets (three stories administered consecutively each day). The self-assessment schedule is provided in supplementary materials.

Participants listened to pre-recorded ASRTs and retold stories in as much detail as they could remember, immediately after presentation of each story and after a delay. Task responses were recorded on the app and automatically uploaded to a secure server.

Minimal bounds were set on the dataset size required to train flexible models with many parameters but strong representations (20 participants per group). Power calculations completed using the pROC package in R, with power specified at 80% and significance set at 0·05, indicated that for full sample analyses an AUC of 0·67 would be detectable with n=40 participants in each group. Using similar parameters, an AUC of 0·74 would be detectable with a n=20 participants in smaller subgroup analyses.

Key outcome measures included the AI-based index test result, identifying: (1) Short ASRT triplets (immediate recall,automatically transcribed) were primary measures of interest. These were experienced as lower burden by participants, yielding higher compliance and a greater number of datapoints for model training and analysis. Long ASRT stories and delayed recall were also examined.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Overview of the AI system

The AI system was based on the "edit encoder" of the ParaBLEU model 18 , the state-of-theart for paraphrase evaluation. Given two input texts, the edit encoder outputs a vector-based representation of the abstract, generalized patterns that differ between them. On an established paraphrase quality benchmark, models using ParaBLEU numerical representations correlate more strongly with human judgements than other existing metrics 18 . Differing from the standard ParaBLEU setup, the model was pretrained with longer paraphrase examples to mirror the length of source-retelling pairs, and without the entailment component of the loss function as entailment labels were unavailable for the updated pretraining dataset. The base model of the edit encoder used a pretrained Longformer model rather than a pretrained RoBERTa model, to accommodate longer texts.

Although adherence varied across participants, ASRTs have high parallel forms reliability, and modest practice effects, indicating that story triplets can be substituted for one another (Skirrow et al,submitted) 19 . One complete long and one complete short triplet (comprising six retellings per triplet: three immediate and three delayed) were picked randomly and uniformly for each participant across assessment days for onward analysis. Long and short triplets and immediate and delayed recall were examined separately.

Responses were transcribed manually and with an out-of-the-box automatic speech recognition (ASR) system. Analyses were completed in Python, using a proprietary framework built using PyTorch.

For each retelling, two representations were derived, based on non-redundant differences between the target (story text) and retelling (target→retelling and retelling→target) as represented by the ParaBLEU model. Classifiers were trained using logistic regression models with the sklearn package in Python to predict pairs of labels (MCI/mild AD or CU;

A + or A -) with tournament leave-pair-out cross-validation analysis (TLPO) 20 . The TLPO process was run twice -once per representation -to obtain two sets of participant-level scores. These are ensembled by simple averaging. To augment the training sample, participants completing any remote assessments (including only partially completed ASRT All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Clinical and biomarker discrimination of models Participant-level scores were ensembled across the three stories per triplet (immediate or delayed recall) to create participant level predictions. These were used to create a ranking for receiver operating characteristic (ROC) curve analysis. The AI system was compared to two comparison models, (1) a demographic comparison (age, sex and years of education)

and (2) PACC5 prediction PACC5 z-scores were predicted from speech samples, trained with leave-one-out crossvalidation using ridge regression models with polynomial kernels. The Pearson correlation coefficient between predicted and actual PACC5 scores was computed.

Screening for MCI was simulated in a hypothetical age 65+ sample (n=1000) with proportional representation of each age group representative of the US population 22 , and MCI prevalence estimates by age from prior meta-analysis 23 . The AI system's (short stories, immediate recall, ASR) sensitivity and specificity within the sample was determined at Youden's index, and compared to physician subjective judgement and MMSE reported in prior research 24 . Methods are described in supplementary materials.

The study was funded by Novoic, a clinical late-stage digital medtech company developing AI-based speech biomarkers. The funder of the study provided financial support towards collection and analysis of the data and was involved in study design, data interpretation and writing of the report. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

Participant recruitment is presented in figure 1 . Two hundred participants were recruited, with 88% with A status confirmed by PET scan (176/200). At least one complete optional remote self-assessment was completed by 86% (115/133). Overall engagement with daily testing was high (mean of 77% in full sample; 78% in CU and 66% in MCI/mild AD).

Those who did not complete remote assessments were more commonly diagnosed with MCI/mild AD (χ²=5·49, p=0·01) and had lower CDR-G scores (r=-0·19, p=0·04). However, they did not differ in age (r=-0·15, p-0·12), education level (r=-0·005, p=0·96), male/female ratio (χ²=0·004, p=0·95), A +/A -ratio (χ²=0·96, p=0·33) or MMSE score (r=-0·15, p=0·11).

The MCI/mild AD participant group comprised primarily MCI participants, with only ten individuals (20·4%) having a diagnosis of mild AD.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in better A signal when examined within more homogeneous groups. MCI classification using the AI system in the full sample yielded an AUC of 0·85 (figure 2B).

AI system performance did not differ depending on automatic versus manual transcription, and results were broadly consistent for long ASRT stories and delayed recall (table 2; supplementary figures). Demographic comparison performed consistently worse than the AI system ( figure 2, table 2) , with confidence intervals incorporating chance level, with the exception of amyloid prediction in the MCI subsample. As compared with the AI system, the PACC5 comparison delivered subtly but non-significantly higher AUCs for detecting MCI in the full sample, but similar performance for A status in MCI and poorer performance for A status in CU (figure 2). All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in AI system (ASR) 0·55 +/-0·12 0·83 +/-0·08* 0·86 +/-0·12 0·53 +/-0·15 AI system (manual) 0·59 +/-0·12 0·85 +/-0·08* 0·88 +/-0·10 0·50 +/-0·15 Demographic comparison 0·62 +/-0·11 0·57 +/-0·12 0·75 +/-0·16 0·45 +/-0·15

Comparison of performance of the AI system for classifying (A) Amyloid beta in the full sample, (B) MCI in the full sample, (C) Amyloid beta in the MCI subsample, and (D) Amyloid beta in the CU subsample, using immediate and delayed recalls of short and long ASRT triplets as input. Difference between AI system and demographic comparison *p<0·0001. CU: cognitively unimpaired; MCI: mild cognitive impairment; ASRT: automatic story recall task; ASR: automatic speech recognition -automatically transcribed; manual: manually transcribed.

The Pearson correlation between AI-model predicted and actual PACC-5 z scores was 0.74.

All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

In a simulated population sample age 65+ (MCI prevalence 16%), in comparison with unassisted physician judgement 24 , routine screening using the AI system (short stories, immediate recall) would increase correct referral rates in primary care by 56.0%, and reduce incorrect referrals by 26·5%; in comparison with screening via the MMSE 24 the AI system would increase correct referral from primary care by 52·9%.

Research documents changes in vocal and linguistic speech patterns in AD, primarily in cohorts with more progressed AD and without biomarker confirmation 13, 25 . The current findings show detectable changes in speech occurring earlier in the disease process. Furthermore, we find modest but detectable differences in speech relating to changes associated with A positivity.

For the lowest burden assessments (short stories, immediate recall), the AI system predicted MCI (AUC 0.85) and A positivity in MCI and CU participant groups (AUC 0·73 and 0·71, respectively), but with A predictions in the full sample being no better than random. This could be due to more subtle impairments associated with A positivity, which may be obscured by broader changes seen accompanying MCI. The AI system consistently outperformed the demographic comparison and performed as well as, or better than, a lengthy supervised test battery developed to detect cognitive changes in preclinical AD (PACC5).

AI system results were consistent across manual and ASR transcription. MCI prediction was consistent for long and short ASRTs and immediate and delayed recall. A status prediction was not as consistent across task variants and groups: in cognitively unimpaired participants the AI system performed well for for short, but not long, ASRTs; predictions of A status in MCI was above random for all task variants, but in the presence of an elevated demographic comparison. These results may indicate differential task difficulty effects interacting with demographic and clinical-biomarker groupings.

In the context of potential improvement in outcomes through lifestyle and medical interventions 26 , and the availability of new amyloid-targeting medications, early detection of AD and clear disease indication matters. However, in clinical practice, AD is not routinely screened for 27 and is underdiagnosed even at the dementia stage 28 . Compared with All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in standard-of-care assessments for MCI, routine screening using the AI system could increase correct referrals by up to 56·0% and reduce incorrect referrals by 26·5%.

Speech assessments that were unsupervised, self-administered and analysed with an automated pipeline. Remote, unsupervised testing can improve inclusivity, increase standardisation and provide access to more advanced testing without the need for extensive experience of neuropsychological workup. Furthermore, speech-based AI models present as a potentially attractive low-cost and low-burden screen for A positivity. Combining the algorithm with other risk factors (e.g. age, APOE genotype) could further increase discriminative power.

We recruited participants with prior amyloid PET and CSF amyloid test results and clinical diagnoses. With increasing A positivity with age 29 , conversion may have occurred for some participants in the interim period. CSF and PET A positivity are differentially associated with cognitive decline, suggesting that they may be optimally sensitive at different disease stages 30 . Similarly, variation in diagnostic criteria for MCI/Mild AD (between trials where participants were recruited from) is likely to have introduced increased variability in our diagnostic reference standards. Even a small number of false labels can impact training of AI systems, and improvements in model performance could be expected with concurrent and consistent reference standards.

Although uptake of optional remote assessment was high, non-completion was associated with greater CDR-G indexed clinical impairment and was more common in MCI/Mild AD participants. Remote, unsupervised cognitive assessments may be challenging for individuals with more progressed cognitive impairment. For these subjects, supervised testing in clinic or via telemedicine may be more appropriate.

Test engagement varied from day to day and, as a result, our analyses included test results from different ASRT stimuli and testing days across different participants. Variability introduced by differences in the story stimuli themselves, and practice effects, may have affected sensitivity of the AI system. However, this approach allowed us to maximise the sample available, and enabled us to develop stimulus-agnostic AI models, which can be applied across a class of stimuli.

Our AI system was developed and tested within a British English speaking sample, selected to exclude concurrent neurological and mental health conditions. Validation is now needed in All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 20, 2021. ; https://doi.org/10.1101/2021.10.19.21264878 doi: medRxiv preprint more clinically heterogeneous samples and across different accents and languages. Largerscale studies are needed to confirm and refine our results. We expect significant performance improvements in the AI system with a larger training dataset, increasing power to detect more subtle changes in speech patterns. 

The study protocol was designed by EF, MM, and JW. The research study and data collection was coordinated by MM. Software was developed by JW, UM, RL and EF.

Underlying data was verified by all authors (data acquisition and completeness MM, database management UM, quality control CS, data generated by analytic models JW, EF, UM, and RL). Analyses were completed by RL, CS, UM, JW, and EF. The first draft of the manuscript was completed by EF and CS. All authors contributed to the revision of the manuscript.

The study was funded by Novoic, a clinical late-stage digital medtech company developing AI-based speech biomarkers. The funder of the study provided financial support towards collection and analysis of the data and was involved in study design, data interpretation and writing of the report.

Speech data is identifiable and cannot be shared, but all deidentified quantitative participant data shown in the present study are available upon reasonable request to the authors. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

Detection of β-amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers

Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group

Regulatory innovation and drug development for early-stage Alzheimer's disease

Guideline on the clinical investigation of medicines for the treatment of Alzheimer's disease

Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5

Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis

Proper names from story recall are associated with beta-amyloid in cognitively unimpaired adults at risk for Alzheimer's disease

Serial position effects in the Logical Memory Test: Loss of primacy predicts amyloid positivity

Getting the hang of it: preferential gist over verbatim story recall and the roles of attentional capacity and the episodic buffer in Alzheimer disease

Spoken language derived measures for detecting mild cognitive impairment

Fully Automated Neuropsychological Assessment for Detecting Mild Cognitive Impairment

Artificial intelligence, speech, and language processing approaches to monitoring alzheimer's disease: A systematic review

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Mini-mental state" A practical method for grading the cognitive state of patients for the clinician

The Clinical Dementia Rating (CDR): current version and scoring rules

Generative Pretraining for Paraphrase Evaluation

Validation of a novel fully automated story recall task for repeated remote high-frequency administration

An experimental comparison of cross-validation techniques for estimating the area under the ROC curve

Fast implementation of delong's algorithm for comparing the areas under correlated receiver operating characteristic curves

Resident population of the United States by sex and age as of

Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

Cost effectiveness of using cognitive screening tests for detecting dementia and mild cognitive impairment in primary care

Ten years of research on automatic voice and speech analysis of people with alzheimer's disease and mild cognitive impairment: A systematic review article

Dementia prevention, intervention, and care: 2020 report of the Lancet Commission

Alzheimer's facts and figures

Underdiagnosis of dementia in primary care: variations in the observed prevalence and comparisons to the expected prevalence